News

The primary goal of the phase I study was to evaluate safety and pharmacokinetic properties of XTL-6865 in patients with chronic hepatitis C. XTL-6865, which targets the E2

International Vaccine Institute (IVI) was established to accelerate development and introduction of vaccines to the developing world and to transfer new technologies to vaccine producers. The development of

WelChol is currently indicated for the reduction of LDL-C either alone or in combination with commonly prescribed statins such as Lipitor, Zocor, Pravachol and Mevacor. A study recently

Protox believes the drug's unique mechanism of action could change the way patients with enlarged prostate are treated. It said that the drug, PRX302, could be used to

<p>Genentech will exercise exclusive licenses to specific targets and use Seattle Genetics&#0039; antibody-drug conjugate (ADC) technology. ADCs utilize the targeting ability of monoclonal antibodies to deliver potent, cell-killing

The companies said that data from recently completed clinical studies suggest that the overall profile for gaboxadol in insomnia does not support further development. As a result of

Schering-Plough is solely responsible for further development and commercialization of this inflammatory disease candidate. However, Pharmacopeia is eligible to receive additional milestone payments if the program advances further

The program compared Cleviprex to current intravenous antihypertensive agents: nitroglycerin, sodium nitroprusside or nicardipine. Cleviprex met all primary endpoints in the trial. “Given the trial successfully met all

The companies have initiated this trial based on preliminary safety results from ongoing phase Ib trials evaluating belinostat in combination with Velcade. The phase II trial will assess